Acutely psychotic patients receiving high-dose haloperidol therapy
Autor: | Kathryn Coulter, Gary Remington, George Voineskos, Bruce G. Pollock, Ken Reed |
---|---|
Rok vydání: | 1993 |
Předmět: |
Adult
Male medicine.medical_specialty Psychosis Bipolar Disorder Adolescent medicine.medical_treatment Irritability Internal medicine Haloperidol Dose Brief Psychiatric Rating Scale medicine Haloperidol Humans Pharmacology (medical) Dosing Psychiatric Status Rating Scales Chemotherapy Dose-Response Relationship Drug business.industry Dopamine antagonist Middle Aged medicine.disease Psychiatry and Mental health Crisis Intervention Psychotic Disorders Anesthesia Acute Disease Schizophrenia Female Schizophrenic Psychology medicine.symptom business medicine.drug |
Zdroj: | Journal of clinical psychopharmacology. 13(1) |
ISSN: | 0271-0749 |
Popis: | Despite the trend towards lower neuroleptic dosing in the treatment of psychosis, there continue to be patients who are administered doses that are higher than recommended. Thirty-six acutely psychotic patients receiving parenteral haloperidol were evaluated by the Brief Psychiatric Rating Scale, the Schedule for Affective Disorders and Schizophrenia-Change Version, and the Nurses' Observation Scale for Inpatient Evaluation, as well as by drug levels in plasma. Patients were compared on the basis of total haloperidol dose in the first 24 hours: regular dose (RD: 10-30 mg) and high dose (HD: 40-80 mg). At baseline, patients in the HD group scored significantly higher on the Brief Psychiatric Rating Scale factor Hostile-Suspiciousness and the Nurses' Observation Scale for Inpatient Evaluation factor Irritability. Assignment to regular-dose and HD groups could not be accounted for on the basis of age, gender, weight, or duration of illness. Moreover, drug levels in plasma indicated that the HD patients did not require higher doses on the basis of differences in haloperidol levels. |
Databáze: | OpenAIRE |
Externí odkaz: |